High Frequencies of Exposure to the Novel Human Parvovirus PARV4 in Hemophiliacs and Injection Drug Users, as Detected by a Serological Assay for PARV4 Antibodies | Zendy

Colin Sharp | Zendy; Alice Lail | Zendy; Sharyne Donfield | Zendy; Ruth Simmons | Zendy; Clifford Leen | Zendy; Paul Klenerman | Zendy; Eric Delwart | Zendy; Edward D. Gomperts | Zendy; Peter Simmonds | Zendy

Open Access

High Frequencies of Exposure to the Novel Human Parvovirus PARV4 in Hemophiliacs and Injection Drug Users, as Detected by a Serological Assay for PARV4 Antibodies

Author(s) -

Colin Sharp,

Alice Lail,

Sharyne Donfield,

Ruth Simmons,

Clifford Leen,

Paul Klenerman,

Eric Delwart,

Edward D. Gomperts,

Peter Simmonds

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/605646

Subject(s) - parvovirus , antibody , virology , seroconversion , immunology , clotting factor , serology , virus , biology , transmission (telecommunications) , medicine , electrical engineering , engineering

PARV4 is a human parvovirus that was first detected in and cloned from an individual with a human immunodeficiency virus (HIV) seroconversion-like illness and that subsequently persisted in the lymphoid tissue and bone marrow. In contrast to human parvovirus B19 infections, PARV4 infections are most frequently detected in injection drug users (IDUs), particularly those who are coinfected with HIV type 1 (HIV-1). To investigate the routes of transmission of PARV4 and to ascertain whether infections are acquired through plasma-derived blood products, we developed a novel anti-PARV4 enzyme-linked immunosorbent assay (ELISA) to determine its seroprevalence in subjects with parenteral exposure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research